23 hours IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche Investor's Business Daily
TG Therapeutics rallied Wednesday after Roche’s rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.
The post IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche appeared first on Investor's Business Daily.